Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells
2014; Wiley; Volume: 47; Issue: 3 Linguagem: Inglês
10.1111/cpr.12103
ISSN1365-2184
AutoresJian Bai, Miao Ma, Mingjun Cai, Feifei Xu, Jiaxiang Chen, Guolan Wang, Xiaoming Shuai, Kaixiong Tao,
Tópico(s)Genomics and Chromatin Dynamics
ResumoAbstract Objectives Enhancer of zeste homologue 2 ( EZH 2) is crucially involved in epigenetic silencing by acting as a histone methyltransferase. Although EZH 2 is overexpressed in many cancers and is involved in malignant cell proliferation and invasion, the role of EZH 2 in senescence induced by DNA damage has up to now remained largely unknown. In this study, we sought to explore the outcome of EZH 2 depletion along with exposure of doxorubicin ( DOX ), and related mechanisms, in gastric cancer cells. Materials and methods Here, senescence induced by DNA damage was achieved in gastric cancer cells by DOX treatment. EZH 2 was downregulated by transfection with siRNA or treated with (‐)‐epigallocatechin‐3‐gallate, a targeted inhibitor. Senescence‐associated β galactosidase (SA‐β‐gal) and formation of senescence‐associated heterochromatin foci were used to identify cell senescence. To investigate effects of EZH 2 depletion on the cell cycle, apoptosis and proliferation, flow cytometry and MTT analysis were employed. Changes in p53–p21 axis activation were detected by Western blotting. Results We found that cell proliferative arrest caused by DOX could be promoted by EZH 2 depletion. Mechanistically, EZH 2 depletion not only worked in coordination with DNA damage during the progression of cell senescence but also promoted apoptosis in p53 mutant cells. However, it had no cooperative relationship with DOX in p53 wild‐type cells. Conclusions These data help unravel a crucial role for EZH 2 in senescence and apoptosis in gastric cancer cells and that p53 genomic status was associated with different cell responses to EZH 2 silencing.
Referência(s)